Alpha Tau Medical Ltd (Alpha Tau) is medical technology company that focuses on the discovery, development and marketing of Alpha DaRT (diffusing alpha-emitters radiation therapy) seed for the treatment of solid cancers. The company is evaluating Alpha DaRT therapy for the treatment of skin cancer, oral cavity cancer, head-and-neck cancer and breast cancer in clinical studies. It offers cancer treatment services. It is advancing its clinical trials at cancer centers in Canada, Israel, Japan, Russia and France. The company is also investigating DaRT in pre-clinical trials as a combination with chemotherapy to combat local and metastatic cancer. Alpha Tau Medical is headquartered in Tel Aviv, Israel.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Alpha Tau Medical Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Alpha Tau Medical Ltd Company Overview
- Alpha Tau Medical Ltd Company Snapshot
- Alpha Tau Medical Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Alpha Tau Medical Ltd - Pipeline Analysis Overview
- Alpha Tau Medical Ltd - Key Facts
- Alpha Tau Medical Ltd - Major Products and Services
- Alpha Tau Medical Ltd Pipeline Products by Development Stage
- Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status
- Alpha Tau Medical Ltd Pipeline Products Overview
- Alpha DaRT Kit - Breast cancer
- Alpha DaRT Kit - Breast cancer Product Overview
- Alpha DaRT Kit - Breast cancer Clinical Trial
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia Product Overview
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia Clinical Trial
- Alpha DaRT Kit - Head And Neck Cancer
- Alpha DaRT Kit - Head And Neck Cancer Product Overview
- Alpha DaRT Kit - Head And Neck Cancer Clinical Trial
- Alpha DaRT Kit - Liver Cancer
- Alpha DaRT Kit - Liver Cancer Product Overview
- Alpha DaRT Kit - Liver Cancer Clinical Trial
- Alpha DaRT Kit - Neoadjuvant Rectal Cancer
- Alpha DaRT Kit - Neoadjuvant Rectal Cancer Product Overview
- Alpha DaRT Kit - Pancreatic Cancer
- Alpha DaRT Kit - Pancreatic Cancer Product Overview
- Alpha DaRT Kit - Pancreatic Cancer Clinical Trial
- Alpha DaRT Kit - Prostate Cancer
- Alpha DaRT Kit - Prostate Cancer Product Overview
- Alpha DaRT Kit - Prostate Cancer Clinical Trial
- Alpha DaRT Kit - Recurrent Cervical Cancer
- Alpha DaRT Kit - Recurrent Cervical Cancer Product Overview
- Alpha DaRT Kit - Recurrent Glioblastoma Multiforme
- Alpha DaRT Kit - Recurrent Glioblastoma Multiforme Product Overview
- Alpha DaRT Kit - Recurrent Gynecological Cancer
- Alpha DaRT Kit - Recurrent Gynecological Cancer Product Overview
- Alpha DaRT Kit - Recurrent Prostate Cancer
- Alpha DaRT Kit - Recurrent Prostate Cancer Product Overview
- Alpha DaRT Kit - Recurrent Rectal Cancer
- Alpha DaRT Kit - Recurrent Rectal Cancer Product Overview
- Alpha DaRT Kit - Sarcoma
- Alpha DaRT Kit - Sarcoma Product Overview
- Alpha DaRT Kit - Skin Cancer
- Alpha DaRT Kit - Skin Cancer Product Overview
- Alpha DaRT Kit - Skin Cancer Clinical Trial
- Alpha DaRT Kit - Squamous Cell Carcinoma
- Alpha DaRT Kit - Squamous Cell Carcinoma Product Overview
- Alpha DaRT Kit - Squamous Cell Carcinoma Clinical Trial
- Alpha DaRT Kit - Vulvar Cancer
- Alpha DaRT Kit - Vulvar Cancer Product Overview
- Alpha DaRT Kit - Vulvar Cancer Clinical Trial
- Alpha Tau Medical Ltd - Key Competitors
- Alpha Tau Medical Ltd - Key Employees
- Alpha Tau Medical Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Alpha Tau Medical Ltd, Recent Developments
- May 24, 2023: Alpha Tau Medical to participate in June Investor Conferences
- May 23, 2023: Alpha Tau Medical announces Q1 2023 financial results and provides corporate update
- Nov 22, 2022: Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
- Oct 21, 2022: Alpha Tau announces multiple corporate updates ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
- Sep 01, 2022: Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
- Aug 25, 2022: Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
- Aug 22, 2022: Alpha Tau and MIM Software announce collaboration for Alpha DaRT Treatment Planning
- Jun 16, 2022: Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site
- Jun 07, 2022: Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors
- May 26, 2022: Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Alpha Tau Medical Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Alpha Tau Medical Ltd Pipeline Products by Equipment Type
- Alpha Tau Medical Ltd Pipeline Products by Indication
- Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status
- Alpha Tau Medical Ltd, Key Facts
- Alpha Tau Medical Ltd, Major Products and Services
- Alpha Tau Medical Ltd Number of Pipeline Products by Development Stage
- Alpha Tau Medical Ltd Pipeline Products Summary by Development Stage
- Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status
- Alpha Tau Medical Ltd Ongoing Clinical Trials Summary
- Alpha DaRT Kit - Breast cancer - Product Status
- Alpha DaRT Kit - Breast cancer - Product Description
- Alpha DaRT Kit - Breast cancer - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients with Distant Metastases
- Alpha DaRT Kit - Breast cancer - Study to Evaluate the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - Product Status
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - Product Description
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
- Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Preliminary Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia
- Alpha DaRT Kit - Head And Neck Cancer - Product Status
- Alpha DaRT Kit - Head And Neck Cancer - Product Description
- Alpha DaRT Kit - Head And Neck Cancer - A Study to Evaluate the Efficacy of Neoadjuvant DaRT for Locally Advanced Oral Cavity Squamous Cell Carcinoma
- Alpha DaRT Kit - Liver Cancer - Product Status
- Alpha DaRT Kit - Liver Cancer - Product Description
- Alpha DaRT Kit - Liver Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Liver Metastases
- Alpha DaRT Kit - Neoadjuvant Rectal Cancer - Product Status
- Alpha DaRT Kit - Neoadjuvant Rectal Cancer - Product Description
- Alpha DaRT Kit - Pancreatic Cancer - Product Status
- Alpha DaRT Kit - Pancreatic Cancer - Product Description
- Alpha DaRT Kit - Pancreatic Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer
- Alpha DaRT Kit - Pancreatic Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters on Advanced Pancreatic Cancer
- Alpha DaRT Kit - Prostate Cancer - Product Status
- Alpha DaRT Kit - Prostate Cancer - Product Description
- Alpha DaRT Kit - Prostate Cancer - A Feasibility of Neoadjuvant Interstitial Brachytherapy (Ibt) Using Diffusing Alpha Emitters Radiation Therapy (Dart) Seeds in Men With Prostate Cancer
- Alpha DaRT Kit - Recurrent Cervical Cancer - Product Status
- Alpha DaRT Kit - Recurrent Cervical Cancer - Product Description
- Alpha DaRT Kit - Recurrent Glioblastoma Multiforme - Product Status
- Alpha DaRT Kit - Recurrent Glioblastoma Multiforme - Product Description
- Alpha DaRT Kit - Recurrent Gynecological Cancer - Product Status
- Alpha DaRT Kit - Recurrent Gynecological Cancer - Product Description
- Alpha DaRT Kit - Recurrent Prostate Cancer - Product Status
- Alpha DaRT Kit - Recurrent Prostate Cancer - Product Description
- Alpha DaRT Kit - Recurrent Rectal Cancer - Product Status
- Alpha DaRT Kit - Recurrent Rectal Cancer - Product Description
- Alpha DaRT Kit - Sarcoma - Product
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Fore Biotherapeutics Inc
- Technion Technology Transfer
- Champions Oncology (Israel) Limited
- Technion Technology Transfer
- Fore Biotherapeutics Inc
- Champions Oncology (Israel) Limited
